BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 32525730)

  • 41. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
    Schuster SJ; Bishop MR; Tam CS; Waller EK; Borchmann P; McGuirk JP; Jäger U; Jaglowski S; Andreadis C; Westin JR; Fleury I; Bachanova V; Foley SR; Ho PJ; Mielke S; Magenau JM; Holte H; Pantano S; Pacaud LB; Awasthi R; Chu J; Anak Ö; Salles G; Maziarz RT;
    N Engl J Med; 2019 Jan; 380(1):45-56. PubMed ID: 30501490
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Impact of Bridging Chemotherapy on Clinical Outcomes of CD19-Specific CAR T Cell Therapy in Children/Young Adults with Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia.
    Shahid S; Ramaswamy K; Flynn J; Mauguen A; Perica K; Park JH; Forlenza CJ; Shukla NN; Steinherz PG; Margossian SP; Boelens JJ; Kernan NA; Curran KJ
    Transplant Cell Ther; 2022 Feb; 28(2):72.e1-72.e8. PubMed ID: 34852305
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Tisagenlecleucel Therapy: Nursing Considerations for the Outpatient Setting.
    Cunningham K; DiFilippo H; Henes K; Irwin LL; Napier E; Weber E
    Semin Oncol Nurs; 2021 Aug; 37(4):151178. PubMed ID: 34340892
    [TBL] [Abstract][Full Text] [Related]  

  • 44. FDA Approval Summary: Tisagenlecleucel for Treatment of Patients with Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia.
    O'Leary MC; Lu X; Huang Y; Lin X; Mahmood I; Przepiorka D; Gavin D; Lee S; Liu K; George B; Bryan W; Theoret MR; Pazdur R
    Clin Cancer Res; 2019 Feb; 25(4):1142-1146. PubMed ID: 30309857
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Multiply Relapsed or Refractory Adult Large B-Cell Lymphoma.
    Lin JK; Muffly LS; Spinner MA; Barnes JI; Owens DK; Goldhaber-Fiebert JD
    J Clin Oncol; 2019 Aug; 37(24):2105-2119. PubMed ID: 31157579
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma.
    Pasquini MC; Hu ZH; Curran K; Laetsch T; Locke F; Rouce R; Pulsipher MA; Phillips CL; Keating A; Frigault MJ; Salzberg D; Jaglowski S; Sasine JP; Rosenthal J; Ghosh M; Landsburg D; Margossian S; Martin PL; Kamdar MK; Hematti P; Nikiforow S; Turtle C; Perales MA; Steinert P; Horowitz MM; Moskop A; Pacaud L; Yi L; Chawla R; Bleickardt E; Grupp S
    Blood Adv; 2020 Nov; 4(21):5414-5424. PubMed ID: 33147337
    [TBL] [Abstract][Full Text] [Related]  

  • 47. How much does the hospital stay for infusion of anti-CD19 CAR-T cells cost to the French National Health Insurance?
    Huguet M; Raimond V; Kaltenbach E; Augusto V; Perrier L
    Bull Cancer; 2021 Dec; 108(12):1170-1180. PubMed ID: 34561025
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Tisagenlecleucel vs. historical standard of care in children and young adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
    V Stackelberg A; Jäschke K; Jousseaume E; Templin C; Jeratsch U; Kosmides D; Steffen I; Gökbuget N; Peters C
    Leukemia; 2023 Dec; 37(12):2346-2355. PubMed ID: 37880478
    [TBL] [Abstract][Full Text] [Related]  

  • 49. CD19-targeted chimeric antigen receptor T-cell therapy for CNS relapsed or refractory acute lymphocytic leukaemia: a post-hoc analysis of pooled data from five clinical trials.
    Leahy AB; Newman H; Li Y; Liu H; Myers R; DiNofia A; Dolan JG; Callahan C; Baniewicz D; Devine K; Wray L; Aplenc R; June CH; Grupp SA; Rheingold SR; Maude SL
    Lancet Haematol; 2021 Oct; 8(10):e711-e722. PubMed ID: 34560014
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Tisagenlecleucel for relapsed/refractory acute lymphoblastic leukemia in the Irish healthcare setting: cost-effectiveness and value of information analysis.
    Carey N; Leahy J; Trela-Larsen L; McCullagh L; Barry M
    Int J Technol Assess Health Care; 2022 Jul; 38(1):e56. PubMed ID: 35815435
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Systematic Review and Meta-analysis of CD19-Specific CAR-T Cell Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia in the Pediatric and Young Adult Population: Safety and Efficacy Outcomes.
    Aamir S; Anwar MY; Khalid F; Khan SI; Ali MA; Khattak ZE
    Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):e334-e347. PubMed ID: 33573914
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma.
    Bishop MR; Dickinson M; Purtill D; Barba P; Santoro A; Hamad N; Kato K; Sureda A; Greil R; Thieblemont C; Morschhauser F; Janz M; Flinn I; Rabitsch W; Kwong YL; Kersten MJ; Minnema MC; Holte H; Chan EHL; Martinez-Lopez J; Müller AMS; Maziarz RT; McGuirk JP; Bachy E; Le Gouill S; Dreyling M; Harigae H; Bond D; Andreadis C; McSweeney P; Kharfan-Dabaja M; Newsome S; Degtyarev E; Awasthi R; Del Corral C; Andreola G; Masood A; Schuster SJ; Jäger U; Borchmann P; Westin JR
    N Engl J Med; 2022 Feb; 386(7):629-639. PubMed ID: 34904798
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Evolving Evidence-Based Value Assessment of One-Time Therapies: Tisagenlecleucel as a Case Study.
    Laetsch T; Zhang J; Yang H; Xie Y; Zhang D; Garrison L
    Appl Health Econ Health Policy; 2024 Apr; ():. PubMed ID: 38683438
    [TBL] [Abstract][Full Text] [Related]  

  • 54. CTL019 (tisagenlecleucel): CAR-T therapy for relapsed and refractory B-cell acute lymphoblastic leukemia.
    Vairy S; Garcia JL; Teira P; Bittencourt H
    Drug Des Devel Ther; 2018; 12():3885-3898. PubMed ID: 30518999
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Health Care Resource Utilization and Total Costs of Care for Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia in the United States: A Retrospective Claims Analysis.
    Ito D; Feng C; Fu C; Kim C; Wu J; Dalton D; Epstein J; Snider JT; DuVall AS
    Clin Ther; 2024 Jan; 46(1):3-11. PubMed ID: 37981560
    [TBL] [Abstract][Full Text] [Related]  

  • 56. More Updates to Come of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial: Could the Statistical Methodology Be Further Improved?
    Tong WH; Mertens BJ
    J Clin Oncol; 2023 May; 41(13):2450-2451. PubMed ID: 36898080
    [No Abstract]   [Full Text] [Related]  

  • 57. Clinical Pharmacology of Tisagenlecleucel in B-cell Acute Lymphoblastic Leukemia.
    Mueller KT; Waldron E; Grupp SA; Levine JE; Laetsch TW; Pulsipher MA; Boyer MW; August KJ; Hamilton J; Awasthi R; Stein AM; Sickert D; Chakraborty A; Levine BL; June CH; Tomassian L; Shah SS; Leung M; Taran T; Wood PA; Maude SL
    Clin Cancer Res; 2018 Dec; 24(24):6175-6184. PubMed ID: 30190371
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Real-world use of tisagenlecleucel in infant acute lymphoblastic leukemia.
    Moskop A; Pommert L; Baggott C; Prabhu S; Pacenta HL; Phillips CL; Rossoff J; Stefanski HE; Talano JA; Margossian SP; Verneris MR; Myers GD; Karras NA; Brown PA; Qayed M; Hermiston ML; Satwani P; Krupski C; Keating AK; Wilcox R; Rabik CA; Fabrizio VA; Chinnabhandar V; Goksenin AY; Curran KJ; Mackall CL; Laetsch TW; Guest EM; Breese EH; Schultz LM
    Blood Adv; 2022 Jul; 6(14):4251-4255. PubMed ID: 35580324
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Tisagenlecleucel-T for the treatment of acute lymphocytic leukemia.
    Thomas X; Paubelle E
    Expert Opin Biol Ther; 2018 Nov; 18(11):1095-1106. PubMed ID: 30296188
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Tisagenlecleucel immunogenicity in relapsed/refractory acute lymphoblastic leukemia and diffuse large B-cell lymphoma.
    Thudium Mueller K; Grupp SA; Maude SL; Levine JE; Pulsipher MA; Boyer MW; August KJ; Myers GD; Tam CS; Jaeger U; Foley SR; Borchmann P; Schuster SJ; Waller EK; Awasthi R; Potthoff B; Warren A; Waldron ER; McBlane F; Chassot-Agostinho A; Laetsch TW
    Blood Adv; 2021 Dec; 5(23):4980-4991. PubMed ID: 34432863
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.